Storia in 2 fonti

Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial

Akeso, Summit say ivonescimab hit the OS bar in China's Phase 3 HARMONi-2 trial vs. Keytruda; full data due at a future meeting.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo8 g fa

Akeso, Summit say ivonescimab hit the OS bar in China's Phase 3 HARMONi-2 trial vs. Keytruda; full data due at a future meeting.

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.